About PharmaReview
PharmaReview is a company based in London (United Kingdom) founded in 2011 by Tessa Pugh and Ralph Carter.. The company has 34 employees as of December 31, 2020. PharmaReview offers products and services including Medical Copy Review Service and LMR Process Support. PharmaReview operates in a competitive market with competitors including Orphalan, NIMBLE Diagnostics, OneroRx, Nutrasource and Catalys Pacific, among others.
- Headquarter London, United Kingdom
- Employees 34 as on 31 Dec, 2020
- Founders Tessa Pugh, Ralph Carter
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Pharmareview Limited
- Date of Incorporation 04 Oct, 2011
- Jurisdiction READING, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
$3.61 M (USD)57as on Dec 31, 2022
-
EBITDA
-
Latest Funding Round
-
Investors
HHS
& 1 more
-
Employee Count
34
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PharmaReview
PharmaReview offers a comprehensive portfolio of products and services, including Medical Copy Review Service and LMR Process Support. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides review and approval of medical materials for compliance.
Assists with lead-up reviews and timely congress material handling.
Unlock access to complete
Unlock access to complete
Funding Insights of PharmaReview
- Total Funding Total Funding
- Total Rounds 6
- Last Round Last Round
-
First Round
First Round
(01 May 2011)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Private Equity Round - PharmaReview | Valuation | Bridgepoint Capital |
|
| Mar, 2015 | Amount | Grant - PharmaReview | Valuation |
investors |
|
| Feb, 2015 | Amount | Grant - PharmaReview | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in PharmaReview
PharmaReview has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and Bridgepoint Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Middle-market businesses up to €1 billion are acquired pan-Europe.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by PharmaReview
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - PharmaReview
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pharmareview Comparisons
Competitors of PharmaReview
PharmaReview operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orphalan, NIMBLE Diagnostics, OneroRx, Nutrasource and Catalys Pacific, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer and provider of access to innovative treatments to patients with rare diseases
|
|
| domain | founded_year | HQ Location |
Non-invasive diagnostic devices for cardiovascular stent monitoring are developed.
|
|
| domain | founded_year | HQ Location |
Telepharmacy services are delivered via an online platform for consultations.
|
|
| domain | founded_year | HQ Location |
Marketing services are provided for healthcare, nutraceutical, and pharmaceutical sectors.
|
|
| domain | founded_year | HQ Location |
Invests in biotech companies via global networks and partnerships for disease treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about PharmaReview
When was PharmaReview founded?
PharmaReview was founded in 2011.
Where is PharmaReview located?
PharmaReview is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
How many employees does PharmaReview have?
As of Dec 31, 2020, the latest employee count at PharmaReview is 34.
What does PharmaReview do?
PharmaReview was established in 2011 by co-founders Tessa Pugh and Ralph Carter in London, United Kingdom. Operations focus on delivering review services for pharmaceuticals within the life sciences sector. Expertise is applied to assess and evaluate drug-related processes, supporting industry compliance and development. The company maintains a presence in the UK, serving clients across related fields without extending into manufacturing or direct research.
Who are the top competitors of PharmaReview?
PharmaReview's top competitors include Droplet, Orphalan and NIMBLE Diagnostics.
What products or services does PharmaReview offer?
PharmaReview offers Medical Copy Review Service and LMR Process Support.
Who are PharmaReview's investors?
PharmaReview has 2 investors. Key investors include HHS, and Bridgepoint Capital.